| 1.1 0 (0%) | 06-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.33 | 1-year : | 1.55 |
| Resists | First : | 1.13 | Second : | 1.33 |
| Pivot price | 1.07 |
|||
| Supports | First : | 1.06 | Second : | 1.01 |
| MAs | MA(5) : | 1.09 |
MA(20) : | 1.06 |
| MA(100) : | 0.95 |
MA(250) : | 2.78 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 66.6 |
D(3) : | 70.3 |
| RSI | RSI(14): 60.8 | |||
| 52-week | High : | 8.07 | Low : | 0.58 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ STSA ] has closed below upper band by 15.2%. Bollinger Bands are 61.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.11 |
| Low: | 1.09 - 1.09 | 1.09 - 1.1 |
| Close: | 1.09 - 1.1 | 1.1 - 1.11 |
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Thu, 18 Jan 2024
FDA Issues Complete Response Letter for Satsuma’s DHE Nasal Powder STS101 to Treat Acute Migraine - NeurologyLive
Sun, 16 Apr 2023
SNBL to Acquire Satsuma Pharmaceuticals - GlobeNewswire
Mon, 14 Nov 2022
Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today? - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 10.4 (%) |
| Held by Institutions | 57.9 (%) |
| Shares Short | 130 (K) |
| Shares Short P.Month | 150 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -49.7 % |
| Return on Equity (ttm) | -104.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -0.56 |
| PEG Ratio | 0 |
| Price to Book value | 0.96 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|